The Impact of Chronic Kidney Disease and Short-Term Treatment with Rosiglitazone on Plasma Cell-Free DNA Levels
Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular disease. Circulating free nucleic acids, known as cell-free DNA (cfDNA), have been proposed as a novel biomarker of cardiovascular risk. The impact of renal impairment on cfDNA levels and whether cfDNA is associated w...
Saved in:
| Main Authors: | Amanda L. McGuire, Nadia Urosevic, Doris T. Chan, Gursharan Dogra, Timothy J. J. Inglis, Aron Chakera |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2014/643189 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RP-HPLC Method for the Simultaneous Estimation of Rosiglitazone and Gliclazide in Tablets
by: G. Rathinavel, et al.
Published: (2009-01-01) -
Comparison of the Effectiveness of Insulin Sensitizing Agents Metformin and Rosiglitazone in PCOS
by: Rıfat Emral, et al.
Published: (2008-06-01) -
Effects of Metformin-Rosiglitazone on Glucose, Coagulation and Fibrinolysis among Diabetics
by: *Okungbowa, M. A. O. and Oyegue O. K.
Published: (2017-09-01) -
Whole‐genome sequencing of cell‐free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas
by: Amanda Frydendahl, et al.
Published: (2025-04-01) -
Rosiglitazone Add-On in Treatment of Depressed Patients with Insulin Resistance: a Pilot Study
by: Natalie L. Rasgon, et al.
Published: (2010-01-01)